Study guide
13.2 Renal and Genitourinary Effects
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
13.2 Renal and Genitourinary Effects
Key Takeaways Explain This Topic AI
Cisplatin, ifosfamide, high-dose methotrexate, vancomycin, and acyclovir are high-yield nephrotoxins; monitor I&O and daily weight, and replace cisplatin-related magnesium wasting as ordered.
Do not invent a single creatinine cutoff as ONCC fact—trend that child's baseline, urine output, and concurrent drugs rather than an adult textbook number.
TLS uric-acid protection uses allopurinol to block new formation and rasburicase to cleave existing uric acid; rasburicase carries a G6PD hemolysis caution.
Hemorrhagic cystitis is early acrolein injury prevented with mesna plus hydration, or late BK virus after allogeneic HSCT; bladder radiation causes later hematuria and fibrosis.
Ifosfamide can cause Fanconi-like wasting of phosphate and bicarbonate. After nephrectomy, protect the solitary kidney. SIADH and DI are signposted by sudden changes in urine volume and sodium.
Last updated: August 2026
TCO IV.A.5 tests renal and genitourinary treatment effects: what cisplatin , ifosfamide , high-dose methotrexate , nephrotoxic antimicrobials, uric acid, mesna , BK virus , bladder radiation, and a solitary kidney after nephrectomy do to urine, electrolytes, and bladder mucosa. This is not the emergency chapter for tumor lysis syndrome (TLS) staging, syndrome of inappropriate antidiuretic hormone secretion (SIADH) , or diabetes insipidus (DI) . Those full playbooks live later. Here the CPHON nurse measures intake and output (I&O) , daily weight , and the color of the urine, and does not invent a single creatinine cutoff as ONCC fact.
A 3-year-old after Wilms tumor nephrectomy, a 12-year-old receiving cisplatin for osteosarcoma who is wasting magnesium, and a teenager on day +45 after allogeneic HSCT with clots in the urine are the pictures.
Drug nephrotoxicity and what you actually monitor
Cisplatin injures proximal tubules. The child may have a rising creatinine, magnesium wasting (and often potassium and calcium wasting), and reduced concentrating ability. Hydration before, during, and after the infusion is the protocol, not a courtesy. Replace magnesium as ordered even when the serum value looks "borderline"—symptoms (cramps, tetany, QTc risk) lag. Do not hang the next cisplatin because last month's creatinine was normal if urine output has fallen and weight is up from third-spacing.
Ifosfamide causes a Fanconi-like proximal tubular wasting: phosphate, bicarbonate, glucose, and amino acids spill into urine. Watch hypophosphatemia, acidosis, and rickets-like bone injury on repeated courses. It is not "just cisplatin again." Ifosfamide also shares hemorrhagic cystitis risk with cyclophosphamide.
High-dose methotrexate can precipitate in tubules when urine is acidic or the child is volume-depleted. Alkalinization, vigorous hydration, timed levels, and leucovorin rescue are the chemotherapy-chapter skills; the renal chapter's point is that delayed clearance is a kidney problem as well as a mucositis problem. Nonsteroidal anti-inflammatory drugs, proton-pump inhibitors, and some penicillins that delay methotrexate clearance still get flagged here.
Vancomycin and acyclovir add drug nephrotoxicity, especially when stacked with platinum, ifosfamide, or a dehydrated toddler. Troughs, hydration, and a second look at the medication list are the nursing moves. Do not treat one printed creatinine number as the ONCC "hold everything" threshold—centers use age-based ranges, cystatin C, and urine output. A doubling from that child's baseline matters more than a textbook adult cutoff.
TLS uric-acid nephropathy is a signpost with two named drugs. Allopurinol blocks new uric acid formation and is the usual prophylaxis. Rasburicase enzymatically cleaves existing uric acid and is used for high-risk or established hyperuricemia. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a rasburicase caution: hemolysis can be severe. Do not give rasburicase as a casual extra in a child from a high-prevalence G6PD population without the team's G6PD plan. Send uric acid samples on ice as the laboratory requires after rasburicase or the value will be falsely low. Full TLS electrolyte titration (potassium, phosphate, calcium) lives in the metabolic-emergency chapter.
Hemorrhagic cystitis, SIADH/DI, and the remaining kidney
Hemorrhagic cystitis (HC) splits in time:
Early, drug: acrolein from cyclophosphamide or ifosfamide . Mesna binds acrolein; hyperhydration and frequent voiding keep the bladder from sitting in toxin. Gross hematuria, clots, and bladder spasm during the alkylator window are HC until proven otherwise. Do not skip mesna because the child "looks well."
Late, viral: BK virus (and sometimes adenovirus) after allogeneic HSCT, often after engraftment. Hematuria, urgency, and clots need viral testing, hydration, platelet support, pain control, and urology for clot retention—not another dose of mesna as the only plan.
Bladder radiation (selected rhabdomyosarcoma and other pelvic fields) causes acute radiation cystitis and later telangiectasias, fibrosis, and hematuria. Teach families that pink urine months after radiation is reportable, not "just a UTI until antibiotics fail."
SIADH (too little water excreted; falling sodium) and DI (too much water excreted; rising sodium, huge urine output) are signposted . Vincristine-associated SIADH and pituitary or hypothalamic injury (craniopharyngioma, germ-cell CNS tumors, surgery, radiation) belong in their emergency sections. In this chapter, notice a sudden change in urine volume and sodium, weigh the child, and escalate rather than coaching "drink more" or "drink less" from memory.
After nephrectomy for Wilms tumor or other renal tumors, the child has a solitary kidney . Precautions: avoid nephrotoxic stacking when another antibiotic will do, treat dehydration aggressively, protect against sports trauma per surgery and oncology guidance, and teach families that over-the-counter ibuprofen is not a casual fever medicine. Blood pressure surveillance belongs in survivorship. Do not treat the remaining kidney as indestructible because "creatinine is still 0.4."
I&O, weight, hematuria, and what families must call about
Daily tools are simple and pediatric: strict I&O , daily weight on the same scale, urine dip or visual inspection for hematuria , and electrolytes that actually include magnesium and phosphate , not only sodium and potassium. A preschooler in a diaper needs weighed diapers, not a guess. Orthostatic dizziness after cisplatin may be magnesium, volume, or both.
Teach call parameters in family language: no urine for longer than the team specified, weight up overnight with swelling, tea-colored or frankly bloody urine, clots, pain with voiding after cyclophosphamide, or a child who is newly polydipsic with huge wet diapers (DI signpost). Do not send a child home after ifosfamide with "drink a lot" and no mesna teaching.
The CPHON product is a nurse who hydrates cisplatin and methotrexate correctly, replaces magnesium, gives mesna on time, thinks BK when late hematuria follows transplant, holds rasburicase for the G6PD question, and protects the solitary kidney—without quoting a single invented creatinine cutoff as if ONCC printed it.
- Exposure Renal or GU picture Nursing watch
- Cisplatin Tubular injury, Mg wasting I&O, weight, Mg replacement, hydration
- Ifosfamide Fanconi-like wasting; HC Phosphate, bicarbonate, mesna
- High-dose methotrexate Precipitation nephrotoxicity Alkalinization, levels, leucovorin
- Vancomycin, acyclovir Drug nephrotoxicity Levels, hydration, stacked risks
- TLS uric acid Crystal nephropathy Allopurinol; rasburicase (G6PD caution)
- Cyclophosphamide / ifosfamide Early HC Mesna plus hydration
- BK virus Late HC post-HSCT Hematuria, viral testing
- Bladder RT / nephrectomy Hematuria; solitary kidney Protect remaining kidney; report pink urine